ENPP2 and hepatocellular carcinoma: The primary strength of this study lies in its demonstration that ATX may be a robust independent predictor of HCC recurrence in patients treated with curative RFA, surpassing the performance of conventional tumor markers, such as AFP and PIVKA‐2.